New strategies to rapidly develop broad-spectrum antiviral therapies are urgently required
for emerging and re-emerging viruses. Host-targeting antivirals (HTAs) that target the …

Emerging and re-emerging RNA viruses occasionally cause epidemics and pandemics
worldwide, such as the on-going outbreak of coronavirus SARS-CoV-2. Existing direct …

Although coronaviruses (CoVs) have long been predicted to cause zoonotic diseases and
pandemics with high probability, the lack of effective anti-pan-CoVs drugs rapidly usable …

Emerging and re-emerging RNA viruses occasionally cause epidemics and pandemics
worldwide, such as the on-going outbreak of the novel coronavirus SARS-CoV-2. Herein, we …

The ongoing pandemic spread of the severe acute respiratory syndrome coronavirus type 2
(SARS-CoV-2) demands skillful strategies for novel drug development, drug repurposing …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent
of coronavirus disease 2019 (COVID-19) and the associated global pandemic resulting in> …

The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
referred to as coronavirus disease 2019 (COVID-19), has caused over 13 million infections …

Abstract The coronavirus disease 2019 (COVID-19) pandemic has created an urgent need
for therapeutics that inhibit the SARS− COV-2 virus and suppress the fulminant inflammation …

The pharmacological management of influenza virus (IV) infections still poses a series of
challenges due to the limited anti-IV drug arsenal. Therefore, the development of new anti …

The nucleoside analog N4-hydroxycytidine (NHC) is the active metabolite of the prodrug
molnupiravir, which has been approved for the treatment of COVID-19. SARS-CoV-2 …